Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viehbacher's supposed failings: from Brazil to Phoenix via Lantus

This article was originally published in Scrip

Executive Summary

It wasn't because he wasn't French enough: failings in execution and communication with the board led to his departure. That is the essence of the message coming from Sanofi over the shock sacking of its CEO Chris Viehbacher by the unanimous decision of its board of directors. The removal was precipitated by media leaks, but had been under consideration since the summer, the company confirmed.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC026768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel